USC Scientists Find 1 Lead cPLA2 Inhibitor for Alzheimer’s Inflammation in APOE4 Carriers
Updated
Updated · ScienceDaily · May 31
USC Scientists Find 1 Lead cPLA2 Inhibitor for Alzheimer’s Inflammation in APOE4 Carriers
1 articles · Updated · ScienceDaily · May 31
USC researchers identified experimental compounds targeting the cPLA2 enzyme, with 1 lead inhibitor cutting harmful inflammatory activity in human brain cells under Alzheimer’s-like stress.
Billions of molecules were screened to find candidates that selectively hit cPLA2 without disrupting related enzymes and were small enough to cross the blood-brain barrier.
Mouse studies showed the lead compound reached the brain and altered neuroinflammatory pathways tied to Alzheimer’s disease, supporting cPLA2 as a drug target.
APOE4 carriers with higher cPLA2 activity were more likely to develop Alzheimer’s, linking the enzyme to risk while highlighting a pathway that may be modulated rather than fully shut down.
The findings, published in npj Drug Discovery, remain preclinical; USC researchers said the next phase will test whether the approach is safe and meaningful in humans.
Can targeting the liver, not the brain, become the next breakthrough for Alzheimer's treatment?
Is a single drug enough to halt Alzheimer's, or is a full metabolic overhaul required?
If the high-risk Alzheimer's gene also harms bones, what other silent damage is it causing?
Targeting Neuroinflammation in Alzheimer’s: BRI-50460 cPLA2 Inhibitor Offers New Hope for APOE4 Carriers
Overview
This report highlights a major breakthrough in Alzheimer's disease research by focusing on chronic neuroinflammation as a key driver of disease progression. Scientists identified the enzyme cPLA2 as a central mediator in harmful inflammatory lipid signaling pathways. By understanding cPLA2's role, researchers at USC used an advanced virtual screening method, V-SYNTHES2, to search through 36 billion compounds and discovered promising new drug candidates. This targeted approach paves the way for innovative therapies that disrupt damaging inflammation in the brain, offering new hope for effective Alzheimer's treatments.